Cynata Therapeutics Limited (ASX:CYP)
Australia · Delayed Price · Currency is AUD 0.0120
-0.0010 (-7.69%)
Aug 5, 2026, 1:13 PM AEST
Cynata Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 2.59 | 5.05 | 6.21 | 16.17 | 23.8 | 26.72 |
Cash & Short-Term Investments | 2.59 | 5.05 | 6.21 | 16.17 | 23.8 | 26.72 |
Cash Growth | -48.74% | -18.62% | -61.62% | -32.06% | -10.92% | 95.73% |
Other Receivables | 0.07 | 0.1 | 0.11 | 0.34 | 0.07 | 0.04 |
Receivables | 0.07 | 0.1 | 0.11 | 0.34 | 0.07 | 0.25 |
Prepaid Expenses | 0.14 | 0.19 | 0.22 | 0.33 | 0.24 | 0.29 |
Other Current Assets | 0 | 0 | 0 | 0.03 | 0.03 | 0.03 |
Total Current Assets | 2.79 | 5.35 | 6.54 | 16.86 | 24.14 | 27.28 |
Long-Term Deferred Charges | 1.72 | 1.85 | 1.85 | 2.13 | 2.41 | 2.69 |
Total Assets | 4.51 | 7.2 | 8.39 | 18.99 | 26.55 | 29.97 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 0.85 | 0.39 | 0.43 | 1.31 | 1.58 | 0.68 |
Accrued Expenses | - | 0.82 | 0.74 | 0.95 | 1.01 | 0.93 |
Total Current Liabilities | 1.12 | 1.22 | 1.17 | 2.26 | 2.59 | 1.6 |
Total Liabilities | 1.12 | 1.22 | 1.17 | 2.26 | 2.59 | 1.6 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 89.51 | 89.52 | 81.62 | 81.62 | 74.9 | 74.9 |
Retained Earnings | -94.37 | -91.71 | -82.32 | -72.57 | -58.3 | -52.85 |
Comprehensive Income & Other | 8.25 | 8.17 | 7.91 | 7.68 | 7.36 | 6.32 |
Shareholders' Equity | 3.39 | 5.98 | 7.22 | 16.73 | 23.96 | 28.37 |
Total Liabilities & Equity | 4.51 | 7.2 | 8.39 | 18.99 | 26.55 | 29.97 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Cash (Debt) | 2.59 | 5.05 | 6.21 | 16.17 | 23.8 | 26.72 |
Net Cash Growth | -48.74% | -18.62% | -61.62% | -32.06% | -10.92% | 95.73% |
Net Cash Per Share | 0.01 | 0.02 | 0.03 | 0.11 | 0.17 | 0.20 |
Filing Date Shares Outstanding | 237.45 | 237.45 | 180.55 | 179.63 | 143.28 | 143.28 |
Total Common Shares Outstanding | 237.45 | 225.95 | 179.63 | 179.63 | 143.28 | 143.28 |
Working Capital | 1.67 | 4.13 | 5.37 | 14.6 | 21.55 | 25.68 |
Book Value Per Share | 0.01 | 0.03 | 0.04 | 0.09 | 0.17 | 0.20 |
Tangible Book Value | 3.39 | 5.98 | 7.22 | 16.73 | 23.96 | 28.37 |
Tangible Book Value Per Share | 0.01 | 0.03 | 0.04 | 0.09 | 0.17 | 0.20 |